Company Overview - Aokada Pharmaceutical Technology Co., Ltd. is a research-driven specialty pharmaceutical company focusing on the development, production, and commercialization of innovative drugs targeting unmet clinical needs in central nervous system diseases, metabolic diseases, and rare diseases [3][4] - The company has developed a proprietary drug delivery platform and an integrated internal system covering research, production, sales, and marketing, with a diverse global product pipeline [3] - Aokada's flagship product, AUC033 (Motpoly XR™), is the first and only FDA-approved once-daily extended-release lacosamide, with a strong focus on epilepsy treatment [3][4] Product Pipeline - Aokada's core products include AUC033 and AUC051, with AUC033 already commercialized and AUC051 in clinical stages, both aimed at treating focal epilepsy [4] - The company has a total of 15 products in its pipeline, with 10 focused on epilepsy, addressing the accessibility gap for epilepsy patients in China [3][4] - Other pipeline products include UAP009A (Vigadrone®) for infantile spasms and complex focal seizures, and several clinical-stage products targeting various neurological and metabolic conditions [4][5] Financial Performance - For the fiscal year 2024, the company reported revenues of approximately 292 million RMB, with a projected revenue of 207 million RMB for the nine months ending September 30, 2024 [6][8] - Research and development expenses for the same periods were approximately 132 million RMB, 91.7 million RMB, and 106 million RMB respectively [7][8] - The company has shown a trend of increasing revenues while managing its R&D expenditures effectively [6][7] Industry Overview - The global central nervous system (CNS) drug market is one of the largest and most complex therapeutic areas, projected to grow from $233.7 billion in 2020 to $258.8 billion by 2024, with a CAGR of 2.6% [9] - The epilepsy drug market specifically is expected to grow from $7.6 billion in 2019 to $8.2 billion by 2024, with a CAGR of 1.4% [12] - The Chinese epilepsy drug market is anticipated to grow from $0.9 billion in 2019 to $1.1 billion by 2024, reflecting a stronger growth rate of 4.2% [13]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Shanghai Aucta Pharmaceuticals Co., Ltd. 上海奧科達醫藥科技股份有限公司 (the "Company") (A joint stock company incorporated in the ...

Shanghai Aucta Pharmaceuticals Co., Ltd. 上海奧科達醫藥科技股份有限公司 香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因依賴該等內容而引 致的任何損失承擔任何責任。 （「本公司」） 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長 註冊的本公司招股章程作出投資決定。招股章程副本將於發售期間向公眾發放。 (a) 本文件僅向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據 本文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其補充、修訂或更換附頁，並不引起本公司、本公司的聯席 保薦人、整體協調人、顧問或包銷團成員在香港或任何其他司法管轄區必須進行發售活 動的責任。本公司最終會否進行任何發售仍屬未知之數； (c) 本文件或其補充、修訂或更換附頁的內容可能會亦可能不會在最後正式的上市文件內全 部或部分轉載； (d) 本申請版本並非最終的上市文件，本公司可能不時根據聯交所證券上市規則作出更新或 ...